Premium
Advance of sporadic Alzheimer's disease animal models
Author(s) -
Zhang Lili,
Chen Chen,
Mak Marvin SH,
Lu Junfeng,
Wu Zeqing,
Chen Qiuhe,
Han Yifan,
Li Yuefeng,
Pi Rongbiao
Publication year - 2020
Publication title -
medicinal research reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.868
H-Index - 130
eISSN - 1098-1128
pISSN - 0198-6325
DOI - 10.1002/med.21624
Subject(s) - disease , dementia , animal model , medicine , clinical trial , drug development , alzheimer's disease , drug , neuroscience , bioinformatics , psychology , pharmacology , biology , pathology
Alzheimer's disease (AD), the most common form of dementia, is a progressive neurodegenerative disease. In the past decades, numbers of promising drug candidates showed significant anti‐AD effects in preclinical studies but failed in clinical trials. One of the major reasons might be the limitation of appropriate animal models for evaluating anti‐AD drugs. More than 95% of AD cases are sporadic AD (sAD). However, the anti‐AD drug candidates were mainly tested in the familial AD (fAD) animal models. The diversity between the sAD and fAD might lead to a high failure rate during the development of anti‐AD drugs. Therefore, an ideal sAD animal model is urgently needed for the development of anti‐AD drugs. Here, we summarized the available sAD animal models, including their methodology, pathologic features, and potential underlying mechanisms. The limitations of these sAD animal models and future trends in the field were also discussed.